Rhumbline Advisers reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 1.4% during the third quarter. The firm now holds 447,928 shares in VRTX, valued at $175.43 million. This adjustment occurs amidst reports of other institutional investors, such as Chesapeake Asset Management LLC and Financial Network Wealth Advisors LLC, increasing their positions in the stock. Conversely, analysts maintain an average "Moderate Buy" rating for VRTX. The average price target for the stock stands at $522.68, indicating analyst confidence in its future prospects. These movements reflect routine adjustments in institutional investment portfolios and an ongoing assessment of Vertex Pharmaceuticals' performance and outlook.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis